MIVI Neuroscience has filed a notice of an exempt offering of securities to raise $9,250,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, MIVI Neuroscience is raising up to $9,250,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Robert Colloton played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About MIVI Neuroscience
The Next Generation of Neurointervention. MIVI is on a mission to deliver groundbreaking solutions for improving outcomes in challenging neurointerventional procedures. We go beyond current options to solve two major unmet needs identified by neurointerventionalists—improving aspiration outcomes for strokes, and reducing distal embolization. Distal occlusions are notoriously difficult to access and treat. MIVI’s mission is to change that equation, by delivering uncompromising performance in even the smallest sizes.
To learn more about MIVI Neuroscience, visit http://www.mivineuro.com/
Contact:
Robert Colloton, Chief Executive Officer
952-944-3834
https://www.linkedin.com/in/bob-colloton-16565628/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.